IFRX
InflaRx N.V.
$2.58
-2.64%
2026-05-08
About InflaRx N.V.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
Key Fundamentals
Forward P/E
-3.37
EPS (TTM)
$-0.80
ROE
-79.9%
Revenue Growth (YoY)
-80.8%
Profit Margin
0.0%
Debt/Equity
2.23
Price/Book
3.77
Beta
1.50
Market Cap
$184.0M
Avg Volume (10D)
4.2M
Recent Breakout Signals
No recent breakout signals detected for IFRX.
Recent Price Range (60 Days)
60D High
$2.94
60D Low
$0.80
Avg Volume
1.3M
Latest Close
$2.58
Get breakout alerts for IFRX
Sign up for Breakout Scanner to receive daily notifications when IFRX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
InflaRx N.V. (IFRX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors IFRX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. IFRX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.